By analyzing data from the Taiwan National Health Insurance Research Database, the use of aspirin or clopidogrel was also significantly associated with better overall survival and disease-free survival for patients with hepatitis B virus (HBV)-related HCC following liver resection surgery. 5 To explore the protective effects of antiplatelet therapy against HCC, Lee et al. conducted a retrospective analysis of the risk of HCC in 1674 patients with CHB and whose HBV DNA levels were suppressed by antivirals to o2000 IU/ml. Risk was compared between patients received antiplatelet treatment (aspirin, clopidogrel or both) and patients who were not treated. The primary and secondary outcomes were development of HCC and bleeding events, respectively. During the study period, the antiplatelet-treated group showed a significantly lower risk of HCC compared to the untreated, regardless of the antiplatelet agent. While treatment with aspirin alone was not associated with a higher bleeding risk, however, antiplatelet therapy containing clopidogrel may increase the overall risk of bleeding. 3 A nationwide cohort study from Taiwan has also concurred that NSAIDs or aspirin use associated with a reduced risk of HCC recurrence. 6 Moreover, an independent study from The National Institutes of Health (NIH) of the United States has also shown that aspirin use was associated with a decreased risk of developing HCC and death from chronic liver disease (CLD), whereas nonaspirin NSAID use was only associated with reduced risk of CLD death. 7 Besides evidence emerging to support aspirin has potential value of chemoprevention, the antitumor effects of aspirin have also been examined. The association between platelets and cancer progression is well recognized and multiple mechanisms have been proposed to explain the complex interactions between platelets and tumor cells. Aspirin is an antiplatelet drug and its anticancer activity has been extensively investigated using cancer cell lines, animal models as well as clinical trials. 8 Randomized controlled trials also showed that aspirin reduced the risk of metastasis of adenocarcinomas, especially in patients with metastatic colorectal cancer. 9 Sorafenib is currently the only FDA-approved molecular inhibitor for the systemic therapy of advanced HCC. However, its high cost, a marginal benefit increase and often severe side effects are the major clinical challenges associated with the treatment of HCC with sorafenib. Being an example of inflammation-related cancer and the chronic inflammatory state in response to liver damage and viral infection appears to be necessary for its initiation and development, the syngergistic therapeutic effect with dual treatment of sorafenib and aspirin has therefore been explored. Aspirin in combination with TACE has been reported to improve overall survival in treating patients with unresectable HCC. 10 Moreover, significant survival improvement was also reported when aspirin was taken at the time of embolization for HCC. 11 Also, there is a current prospective randomized controlled trial registered in China to investigate the effect of sorafenib combined with aspirin in preventing patient risk for postoperative surgical recurrence of HCC (NCT02748304). The primary outcome of the trial is to measure the 5-year overall survival and the secondary outcome is to measure the 5-year disease-free survival and treatment-related bleedings. Unfortunately, the design of most of these trials suffer from the lack of biomarkertargeted selection of subpopulations of HCC patients.
As appropriate patient selection has been implicated to contribute significantly for achieving clinically meaningful results in cancer drug discovery and development, our recent publication addresses the mechanistic aspects of the synergistic effects of aspirin and sorafenib in the combination therapy for HCC. 12 Previous studies have suggested that the observed pro-metastasis effect of sorafenib resulted from the downregulation of the expression of oxidoreductase HTATIP2, a tumor suppressor in HCC and stromal cell-derived factor 1-α (SDF1-α) expression in tumor microenvironment of HCC. Aspirin suppresses COX2 and SDF1-α expression leading to the increase expression of HTATIP2 and therefore counteracts the pro-invasion and pro-metastasis effects of sorafenib in HCC. 13, 14 However, we observed that the expression of HTATIP2 was not significantly modulated when expression data were analyzed in the TCGA-LIHC public data set (http://cancergenome.nih.gov/) and in a data set established in our laboratory for HBV-related HCC (access at Array Express with the codes E-MEXP-84 and E-TABM-292). 15 Therefore, the synergistic antitumor effect observed for aspirin and sorafenib cannot be attributed solely to the upregulation of HTATIP2. In our recent publication, 12 we demonstrated that the synergism observed with combining sorafenib and aspirin was mediated by the repression and activation of specific apoptosis-related genes. We have demonstrated that by combining low-dose sorafenib and aspirin, the synergistic antitumor effects observed are related to the simultaneously silencing of long-chain-fatty-acid CoA ligase 4 (ACSL4) and the induction of growth arrest and DNA damage inducible beta (GADD45B) expression. Furthermore, clinical evidence has independently corroborated that survival of HCC patients expressing ACSL4 high GADD45B low was significantly poorer compared to patients with ACSL4 low GADD45B
high expression, thus demonstrating the potential clinical value of combining aspirin and sorafenib to treat HCC patients expressing ACSL4 high GADD45B low , offering a clear strategy of evidence-driven precision medicine in HCC. In conclusion, aspirin has emerged as a promising chemopreventive and chemotherapeutic agent for HCC.
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